INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30601, 29006, 'Vardenafil', 'Long QT Syndrome', 'Vardenafil prolongs the QT interval.  Patients taking Class 1A or Class III antiarrhythmic medications or those with congenital QT prolongation, should avoid using this agent.  Caution should be exercised if used in patients with congenital QT syndrome, or using other QT prolonging drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30602, 29007, 'Vardenafil', 'Long QT Syndrome', 'Vardenafil prolongs the QT interval.  Patients taking Class 1A or Class III antiarrhythmic medications or those with congenital QT prolongation, should avoid using this agent.  Caution should be exercised if used in patients with congenital QT syndrome, or using other QT prolonging drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30603, 29144, 'Vardenafil', 'Long QT Syndrome', 'Vardenafil prolongs the QT interval.  Patients taking Class 1A or Class III antiarrhythmic medications or those with congenital QT prolongation, should avoid using this agent.  Caution should be exercised if used in patients with congenital QT syndrome, or using other QT prolonging drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30604, 29296, 'Vardenafil', 'Long QT Syndrome', 'Vardenafil prolongs the QT interval.  Patients taking Class 1A or Class III antiarrhythmic medications or those with congenital QT prolongation, should avoid using this agent.  Caution should be exercised if used in patients with congenital QT syndrome, or using other QT prolonging drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30605, 31180, 'Vardenafil', 'Long QT Syndrome', 'Vardenafil prolongs the QT interval.  Patients taking Class 1A or Class III antiarrhythmic medications or those with congenital QT prolongation, should avoid using this agent.  Caution should be exercised if used in patients with congenital QT syndrome, or using other QT prolonging drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30606, 32236, 'Vardenafil', 'Long QT Syndrome', 'Vardenafil prolongs the QT interval.  Patients taking Class 1A or Class III antiarrhythmic medications or those with congenital QT prolongation, should avoid using this agent.  Caution should be exercised if used in patients with congenital QT syndrome, or using other QT prolonging drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30607, 33836, 'Vardenafil', 'Long QT Syndrome', 'Vardenafil prolongs the QT interval.  Patients taking Class 1A or Class III antiarrhythmic medications or those with congenital QT prolongation, should avoid using this agent.  Caution should be exercised if used in patients with congenital QT syndrome, or using other QT prolonging drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30608, 33837, 'Vardenafil', 'Long QT Syndrome', 'Vardenafil prolongs the QT interval.  Patients taking Class 1A or Class III antiarrhythmic medications or those with congenital QT prolongation, should avoid using this agent.  Caution should be exercised if used in patients with congenital QT syndrome, or using other QT prolonging drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30609, 7255, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30610, 7519, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30611, 10684, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30612, 18514, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30613, 25111, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30614, 25112, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30615, 25113, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30616, 25114, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30617, 25115, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30618, 25778, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30619, 26260, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30620, 26261, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30621, 26353, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30622, 28605, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30623, 28981, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30624, 28982, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30625, 28983, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30626, 28984, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30627, 28985, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30628, 28986, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30629, 28987, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30630, 28988, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30631, 28989, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30632, 28990, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30633, 28992, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30634, 28995, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30635, 29005, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30636, 29006, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30637, 29007, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30638, 29144, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30639, 29296, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30640, 31180, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30641, 32236, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30642, 33836, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30643, 33837, 'Vardenafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30644, 7255, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30645, 7519, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30646, 10684, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30647, 18514, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30648, 25111, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30649, 25112, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30650, 25113, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30651, 25114, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30652, 25115, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30653, 25778, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30654, 26260, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30655, 26261, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30656, 26353, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30657, 28605, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30658, 28981, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30659, 28982, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30660, 28983, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30661, 28984, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30662, 28985, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30663, 28986, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30664, 28987, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30665, 28988, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30666, 28989, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30667, 28990, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30668, 28992, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30669, 28995, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30670, 29005, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30671, 29006, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30672, 29007, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30673, 29144, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30674, 29296, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30675, 31180, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30676, 32236, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30677, 33836, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30678, 33837, 'Vardenafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30679, 7255, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30680, 7519, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30681, 10684, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30682, 18514, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30683, 25111, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30684, 25112, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30685, 25113, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30686, 25114, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30687, 25115, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30688, 25778, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30689, 26260, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30690, 26261, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30691, 26353, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30692, 28605, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30693, 28981, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30694, 28982, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30695, 28983, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30696, 28984, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30697, 28985, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30698, 28986, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30699, 28987, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30700, 28988, 'Vardenafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '', 'DDInter', 0);
